Induction immunochemotherapy before definitive chemoradiotherapy versus definitive chemoradiotherapy alone in limited-stage small-cell lung cancer: a multicenter propensity score-matched analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 4/4)
유사 논문P · Population 대상 환자/모집단
372 patients were included: 275 received definitive CRT alone (CRT group) and 97 received induction immunochemotherapy followed by definitive CRT (I-CRT group).
I · Intervention 중재 / 시술
ction immunochemotherapy before definitive chemoradiotherapy
C · Comparison 대조 / 비교
definitive chemoradiotherapy alone in limited
O · Outcome 결과 / 결론
[CONCLUSION] For LS-SCLC, the addition of induction immunochemotherapy to definitive CRT significantly improves clinical outcomes without increasing toxicity. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13014-026-02819-8.
[PURPOSE] The purpose of this study is to evaluate the efficacy and safety of induction immunochemotherapy before definitive chemoradiotherapy (CRT) in patients with limited-stage small-cell lung canc
APA
Hou X, Guo Y, et al. (2026). Induction immunochemotherapy before definitive chemoradiotherapy versus definitive chemoradiotherapy alone in limited-stage small-cell lung cancer: a multicenter propensity score-matched analysis.. Radiation oncology (London, England), 21(1). https://doi.org/10.1186/s13014-026-02819-8
MLA
Hou X, et al.. "Induction immunochemotherapy before definitive chemoradiotherapy versus definitive chemoradiotherapy alone in limited-stage small-cell lung cancer: a multicenter propensity score-matched analysis.." Radiation oncology (London, England), vol. 21, no. 1, 2026.
PMID
41808131
Abstract
[PURPOSE] The purpose of this study is to evaluate the efficacy and safety of induction immunochemotherapy before definitive chemoradiotherapy (CRT) in patients with limited-stage small-cell lung cancer (LS-SCLC).
[MATERIALS AND METHODS] This multicenter retrospective study included patients with LS-SCLC treated with definitive CRT, with or without induction immunochemotherapy from January 2021 to July 2024. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Propensity score matching (PSM) was applied to control potential confounders. Survival was analyzed with Kaplan-Meier method and log-rank tests, and Cox regression was employed for prognostic analysis.
[RESULTS] Overall, 372 patients were included: 275 received definitive CRT alone (CRT group) and 97 received induction immunochemotherapy followed by definitive CRT (I-CRT group). Before PSM, the median OS was 30.3 months in the CRT group vs. not reached (NR) in the I-CRT group, with a 2-year OS of 59.4% vs. 72.2% ( = 0.006). The median PFS was 12.0 months vs. 22.5 months, with a 2-year PFS of 27.1% vs. 47.5%, respectively ( < 0.001). After 1:1 PSM, the median OS was 24.4 months in the CRT group vs. NR in the I-CRT group, with a 2-year OS of 50.1% vs. 70.4% ( = 0.002). The median PFS was 11.8 months vs. 21.9 months, with a 2-year PFS of 25.4% vs. 45.0%, respectively ( = 0.001). There were no significant differences in adverse events between the two groups.
[CONCLUSION] For LS-SCLC, the addition of induction immunochemotherapy to definitive CRT significantly improves clinical outcomes without increasing toxicity.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13014-026-02819-8.
[MATERIALS AND METHODS] This multicenter retrospective study included patients with LS-SCLC treated with definitive CRT, with or without induction immunochemotherapy from January 2021 to July 2024. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Propensity score matching (PSM) was applied to control potential confounders. Survival was analyzed with Kaplan-Meier method and log-rank tests, and Cox regression was employed for prognostic analysis.
[RESULTS] Overall, 372 patients were included: 275 received definitive CRT alone (CRT group) and 97 received induction immunochemotherapy followed by definitive CRT (I-CRT group). Before PSM, the median OS was 30.3 months in the CRT group vs. not reached (NR) in the I-CRT group, with a 2-year OS of 59.4% vs. 72.2% ( = 0.006). The median PFS was 12.0 months vs. 22.5 months, with a 2-year PFS of 27.1% vs. 47.5%, respectively ( < 0.001). After 1:1 PSM, the median OS was 24.4 months in the CRT group vs. NR in the I-CRT group, with a 2-year OS of 50.1% vs. 70.4% ( = 0.002). The median PFS was 11.8 months vs. 21.9 months, with a 2-year PFS of 25.4% vs. 45.0%, respectively ( = 0.001). There were no significant differences in adverse events between the two groups.
[CONCLUSION] For LS-SCLC, the addition of induction immunochemotherapy to definitive CRT significantly improves clinical outcomes without increasing toxicity.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13014-026-02819-8.
같은 제1저자의 인용 많은 논문 (5)
- The SDC1-ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment that Drives Tumor Radioresistance.
- Evaluation of the accuracy of cone-beam CT-based dose calculation for target volumes and organs at risk in left-sided breast cancer radiotherapy.
- Erratum: [Corrigendum] Efficacy of transarterial chemoembolization-hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
- Combination of locoregional and systemic therapy for hepatocellular carcinoma with portal vein tumor thrombus: a real-world retrospective study.
- Xiao-Yao-San suppresses psychological distress-related colorectal cancer metastasis and enhances antitumor immune responses through regulating gut microbiota-bile acid axis.